Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Three-year Safety of Radium-223 in Patients with mCRPC and Symptomatic Bone Metastases
jul 2017 | Uro-oncologie